Keyphrases
Type 2 Diabetes Mellitus (T2DM)
93%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
74%
Precision Medicine
74%
Cardiovascular Disease
68%
Patients with Heart Failure
56%
Heart Failure
51%
Glucose-lowering Drugs
37%
Glucose Metabolic
37%
CV Events
37%
Pooled Cohort Equations
37%
Metabolic Effects
37%
Meta-analysis
37%
Metabolic Traits
37%
Population Cohort Study
37%
Adverse Drug Reaction
37%
Pharmacogenomics
37%
Medicine Drugs
37%
Major Adverse Cardiovascular Events
37%
Clinical Data
37%
Cardiotoxicity
37%
Diverticular Disease
37%
Genomic Data
37%
Chemotherapy
37%
Systematic Meta-analysis
37%
Colovesical Fistula
37%
Imaging Biomarkers
37%
Mendelian Randomization
37%
Cardiovascular Drugs
37%
Nicorandil
37%
Metabolic Risk Factors
37%
Blood Biomarkers
37%
Adverse Effects
31%
Patient Morbidity
31%
Risk Prediction Model
24%
Fistula Symptom
18%
Retinal Photographs
18%
Fractal Dimension
18%
Severe Patients
18%
Retinal Vascular Network
18%
Cardiovascular Risk Assessment
18%
Insulin Resistance
18%
Vascular Parameters
18%
Risk Score
18%
Area under the Curve
18%
Medication Review
18%
Ulcer
18%
Vascular Assessment
18%
Genetic Liability
14%
High Risk
14%
Pleiotropy
14%
Absolute Benefit
14%
Odds Ratio
14%
Clinical Cardiology
12%
Multiple Predictors
12%
Cardiac Stress
12%
Decision Guidance
12%
Therapy Decision Making
12%
Cause of Death
12%
Prescription Drugs
12%
Patients with Cardiovascular Diseases
12%
Large Database
12%
Disease Progression
12%
Reclassification
12%
Pharmacological Management
12%
Adverse Drug Effects
12%
Early Intervention
12%
High-risk Individuals
12%
Adverse Reactions
12%
Primary Care
12%
Biologically Relevant
12%
Daily Challenges
12%
Cardiovascular Risk Markers
12%
Pathophysiological Pathways
12%
Multiple Comorbidities
12%
Drug Efficacy
12%
Risk Model
12%
Medical Therapy
12%
Cardiovascular Risk Prediction
12%
Genetic Risk Score
12%
Risk of Harm
12%
Patient Mortality
12%
Electronic Health Records
12%
Economic Burden
12%
Alternative Therapy
12%
Cardiovascular Events
12%
Avail
12%
Arterial Thrombosis
12%
Inflammation
12%
Endothelial Dysfunction
12%
Advanced Age
12%
Matrix Remodeling
12%
Multiple Biomarkers
12%
Clinical Applicability
12%
Health Systems
12%
Lifestyle Advice
12%
Most Vulnerable
12%
Prediction Model
12%
Drug Susceptibility
12%
Glycemic Control
9%
Glycemia
9%
Cardiovascular Outcomes
9%
Cardio-oncology
9%
Improved Outcomes
9%
Artificial Intelligence Platform
9%
Cardiovascular Effects
9%
Heart Failure Hospitalization
9%
Personalized Approach
9%
Subspecialty
9%
Individual Identification
9%
Aging Population
9%
Retinal Screening
9%
Published Data
9%
Cardiovascular Risk
9%
Scotland
9%
Risk Ratio
9%
Leading Causes of Death
9%
First Year
9%
Semi-automated
9%
Cancer-specific Survival
9%
Glycated Hemoglobin
9%
Genital Infection
9%
Measurement Platform
9%
Sensitivity Analysis
9%
Assessment Platform
9%
Cancer Disease
9%
Polygenic Risk Score
9%
Clinical Scenarios
9%
Coronary Artery Disease
9%
Diabetes Genetics
9%
Type 2 Diabetes Risk
9%
Event Prediction
9%
Prognostic Value
9%
Risk Reduction
9%
Tortuosity
9%
Systemic Anti-cancer Treatment
9%
Hazard Ratio
9%
United Kingdom
9%
Fasting Insulin
9%
Systemic Anti-cancer Therapy
9%
High Cardiovascular Risk
9%
Tayside
9%
Multivariable Cox Regression
9%
Incremental Prognostic Value
9%
Cancer Treatment
9%
Retina
9%
Multivariable Mendelian Randomization
9%
Medicine and Dentistry
Cardiovascular Disease
100%
Maturity Onset Diabetes of the Young
84%
Personalized Medicine
74%
Congestive Heart Failure
74%
Mendelian Randomization Analysis
37%
Cardiovascular Risk
37%
Systematic Review
37%
Cardiotoxicity
37%
Meta-Analysis
37%
Cohort Analysis
37%
Sodium Glucose Cotransporter 2 Inhibitor
37%
Pharmacogenomics
37%
Atherosclerosis
37%
Adverse Drug Reaction
37%
Cardiovascular Agent
37%
Biological Marker
37%
Photograph
28%
Insulin Resistance
16%
Cardiovascular System
15%
Adverse Event
12%
Disease Exacerbation
12%
Clinical Cardiology
12%
Pleiotropy
12%
Drug Efficacy
12%
Combination Therapy
12%
Early Intervention
12%
Prescription Drug
12%
Drug Sensitivity
12%
Electronic Health Record
12%
Genetic Risk
12%
Primary Health Care
12%
Comorbidity
12%
Odds Ratio
12%
Adverse Effect
12%
Oncology
9%
Cancer Survival
9%
Genetics of Diabetes
9%
Malignant Neoplasm
9%
Ischemic Heart Disease
9%
Genital Tract Infection
9%
Hazard Ratio
9%
Proportional Hazards Model
9%
Diabetes
9%
Cancer Treatment
9%
Patient-Data
9%
Cancer Therapy
9%
Glycated Hemoglobin
8%
Artery Thrombosis
5%
Heart Stress
5%
Endothelial Dysfunction
5%
Decision Making
5%
Pharmacology, Toxicology and Pharmaceutical Science
Cardiovascular Disease
90%
sodium glucose cotransporter-2 inhibitors
74%
Non Insulin Dependent Diabetes Mellitus
56%
Congestive Heart Failure
56%
Sodium Glucose Cotransporter 2 Inhibitor
37%
Cardiovascular Agent
37%
Adverse Drug Reaction
37%
Cohort Study
37%
Cystocolic Fistula
37%
Pharmacogenomics
37%
Cardiovascular Risk
37%
Diverticulosis
37%
Diverticulitis
37%
Atherosclerosis
37%
Nicorandil
37%
Biological Marker
37%
Ulcer
18%
Fistula
18%
Disease Exacerbation
17%
Adverse Event
12%
Genetic Risk
12%
Prescription Drug
12%
Combination Therapy
12%
Comorbidity
12%
Genital Tract Infection
9%
Ischemic Heart Disease
9%
Artery Thrombosis
5%
Inflammation
5%
Endothelial Dysfunction
5%
Heart Stress
5%